IN8bio Email Formats

Biotechnology Research • Manhattan, New York, United States • 21-50 Employees

IN8bio Email Formats

IN8bio uses 4 email formats. The most common is {first initial}{last name} (e.g., jdoe@in8bio.com), used 54.5% of the time.

Format	Example	Percentage
{first initial}{last name}	jdoe@in8bio.com	54.5%
{first initial}{second initial}{last name}	jodoe@in8bio.com	18.2%
{last name}{last name}	doedoe@in8bio.com	18.2%
{first initial}.{last name}	j.doe@in8bio.com	9.1%

Key Contacts at IN8bio

William Bio

President, Ceo & Director, Co-Founder

Branimir Popovic

Associate Director, Analytical Development

Sadhak Sengupta

Senior Director, R&D

Mariska Ter Haak

Senior Director Analytical Development

Becca Weekley

Associate Director, Cell Manufacturing Lead

Marsia Silletti

Operations Director

Lloyd Mitchell

Associate Director, Accounting

Samantha Youngblood

Associate Director, Lab Operations

Guoling Chen

Senior Director, Quality Operations

Company overview

Headquarters	Empire State Building, 350 5th Ave Suite 5330, New York , New York 10118, US
Phone number	+16466006438
Website	in8bio.com
NAICS	541714
SIC	873
Keywords	Cell Therapy, Glioblastoma, Solid Tumors, GBM, Ipsc, Allogeneic, Autologous, Gamma Delta T Cells, Drug Resistant Immunotherapy, Genetically Modified Gamma Delta T Cells, Hematological Tumors
Founded	2016
Employees	21-50
Socials

About IN8bio

IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancer. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems, and can intrinsically differentiate between healthy and diseased tissue. IN8bio develops ex vivo-expanded and activated gamma-delta T cells based upon its deep expertise in gamma-delta T cell biology, proprietary genetic engineering, and cell-type specific manufacturing capabilities, which we refer to collectively as our DeltEx platform. IN8bio’s platform employs allogeneic, autologous, and genetically modified approaches to develop novel cell therapies, which are designed to effectively identify and eradicate tumor cells. IN8bio is currently the most clinically advanced gamma-delta T cell company and the first company to bring genetically modified gamma-delta T cells into the clinic. For more information about the Company and its programs, visit www.IN8bio.com.

Employees by Management Level

Total employees: 21-50

Seniority

Employees

Director

Entry

C-Suite

Employees by Department

IN8bio has 8 employees across 6 departments.

Departments

Number of employees

Funding Data

Explore IN8bio's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2024-01-11	14	$14,400,000
2024-11-01	14	$12,400,000

Funding Insights

$26,800,000

Total funding amount

$12,400,000

Most recent funding amount

Number of funding rounds

IN8bio Tech Stack

Discover the technologies and tools that power IN8bio's digital infrastructure, from frameworks to analytics platforms.

theTradeDesk

Advertising

Site Kit

Analytics

Vimeo

Video players

Google Maps

Maps

jQuery Migrate

JavaScript libraries

Twitter Emoji

Font scripts

jQuery

JavaScript libraries

PHP

Programming languages

Akismet

WordPress plugins

WordPress

Blogs

Google Analytics

Analytics

Bootstrap

UI frameworks

Frequently asked questions

IN8bio is located in Manhattan, New York, US.

You can reach IN8bio at +16466006438.

IN8bio was founded in 2016, making it 10 years old. The company has established itself as a significant player in its industry over this time.

IN8bio has approximately 21-50 employees. The company continues to grow its workforce to support its business operations and expansion.

IN8bio has raised a total of $26,800,000 across 2 funding rounds. This investment has helped the company grow and expand its operations.